Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia – Pipeline Review, H2 2016, provides an overview of the Acute Myelocytic Leukemia (Oncology) pipeline landscape.
Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 91, 90, 1, 6, 143, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 14, 24 and 10 molecules, respectively.
Place a direct purchase order on this report at @ http://www.orbisresearch.com/contact/purchase/165812 .
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (Oncology).
– The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Acute Myelocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (Oncology)
Request a sample Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline Review, H2 2016
AB Science SA
Acetylon Pharmaceuticals Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics Sarl
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Agios Pharmaceuticals Inc
Aileron Therapeutics Inc
AIMM Therapeutics BV
Akinion Pharmaceuticals AB
Alexion Pharmaceuticals Inc
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: firstname.lastname@example.org